share_log

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A：其他
美股sec公告 ·  05/13 17:10
Moomoo AI 已提取核心信息
TransCode Therapeutics, Inc., an RNA oncology company, has released an open letter to its shareholders on May 13, 2024, discussing a proposed reverse stock split. The company has filed an amended proxy statement ahead of its Annual Meeting scheduled for June 13, where one of the key proposals is to authorize the Board of Directors to effect a reverse stock split if deemed in the best interest of the company and its shareholders. This proposal comes in response to the company's stock not meeting the Nasdaq Minimum Bid Requirement of closing at $1.00 per share for any ten-day period ended May 6. As a result, Nasdaq has recommended delisting the company's shares. TransCode plans to appeal this decision at a Nasdaq Panel...Show More
TransCode Therapeutics, Inc., an RNA oncology company, has released an open letter to its shareholders on May 13, 2024, discussing a proposed reverse stock split. The company has filed an amended proxy statement ahead of its Annual Meeting scheduled for June 13, where one of the key proposals is to authorize the Board of Directors to effect a reverse stock split if deemed in the best interest of the company and its shareholders. This proposal comes in response to the company's stock not meeting the Nasdaq Minimum Bid Requirement of closing at $1.00 per share for any ten-day period ended May 6. As a result, Nasdaq has recommended delisting the company's shares. TransCode plans to appeal this decision at a Nasdaq Panel Hearing. The reverse stock split is considered a last resort to maintain the company's listing on The Nasdaq Capital Market. The company's stock has recently closed above $1.00 per share for four consecutive days through May 10, but there is no guarantee this will influence the Panel's decision. The letter emphasizes the value of remaining Nasdaq-listed and the company's commitment to taking all necessary steps to achieve this goal.
RNA肿瘤学公司TransCode Therapeutics, Inc. 已于2024年5月13日向其股东发布了一封公开信，讨论了反向股票拆分的提议。公司已在定于6月13日举行的年会之前提交了经修订的委托书，其中一项关键提案是，如果认为符合公司及其股东的最大利益，则授权董事会进行反向股票分割。该提案是对该公司股票在截至5月6日的十天内未达到纳斯达克最低出价要求的回应，即收于每股1.00美元。因此，纳斯达克建议将该公司的股票退市。TransCode计划在纳斯达克小组听证会上对这一决定提出上诉。反向股票拆分被认为是维持公司在纳斯达克资本市场上市的最后手段。截至5月10日，该公司的股票最近连续四天收于每股1.00美元以上，但无法保证这将影响该小组的决定。这封信强调了在纳斯达克继续上市的价值，以及该公司承诺采取一切必要措施来实现这一目标。
RNA肿瘤学公司TransCode Therapeutics, Inc. 已于2024年5月13日向其股东发布了一封公开信，讨论了反向股票拆分的提议。公司已在定于6月13日举行的年会之前提交了经修订的委托书，其中一项关键提案是，如果认为符合公司及其股东的最大利益，则授权董事会进行反向股票分割。该提案是对该公司股票在截至5月6日的十天内未达到纳斯达克最低出价要求的回应，即收于每股1.00美元。因此，纳斯达克建议将该公司的股票退市。TransCode计划在纳斯达克小组听证会上对这一决定提出上诉。反向股票拆分被认为是维持公司在纳斯达克资本市场上市的最后手段。截至5月10日，该公司的股票最近连续四天收于每股1.00美元以上，但无法保证这将影响该小组的决定。这封信强调了在纳斯达克继续上市的价值，以及该公司承诺采取一切必要措施来实现这一目标。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息